STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Van Herk Acquires 1.055M ProQR Shares for $2.30M; Now Holds 13.6%

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Van Herk group disclosed ownership of 14,329,690 ordinary shares of ProQR Therapeutics N.V. (PRQR), representing 13.6% of the company based on 105,344,052 shares outstanding as of June 30, 2025. The filing (Amendment No. 3 to a Schedule 13D) reports that Van Herk Investments B.V. purchased 1,055,000 ordinary shares in open-market transactions from September 5, 2025 to September 29, 2025 for an aggregate net amount of $2,300,635.14 using its general working capital. The reporting group is a network of Netherlands entities and related parties coordinated through Adrianus van Herk, and they state the shares were acquired for investment purposes in the ordinary course of business and that they may review or change their position over time, including engaging with management, acquiring or selling shares, or pursuing other strategic actions.

Positive

  • Material stake disclosed: Beneficial ownership of 14,329,690 shares, representing 13.6% of outstanding shares, a clearly material position.
  • Transparent funding disclosure: Purchases of 1,055,000 shares for an aggregate net amount of $2,300,635.14 funded from VHI's general working capital.

Negative

  • Potential for strategic actions: The Reporting Persons reserve broad rights to engage with management or pursue transactions, which could create uncertainty for other shareholders.
  • Concentrated ownership: A 13.6% block held by a coordinated group may influence governance or strategic outcomes without further disclosure of intentions.

Insights

TL;DR: Van Herk's 13.6% stake is sizable and material; recent open-market purchases added 1.06M shares for $2.30M.

From a shareholder-impact perspective, a disclosed 13.6% beneficial ownership in a small-to-mid cap biotech is material and may attract market attention. The filing confirms active accumulation through open-market trades and that funding came from VHI's working capital. The group frames the holding as investment-oriented but explicitly reserves the right to engage with management or pursue strategic transactions, which introduces potential governance or strategic implications for ProQR. No litigation disclosures or additional transactions in the prior 60 days beyond the reported purchases are noted.

TL;DR: A coordinated Netherlands-based ownership structure controls 13.6% and signals potential for engagement but not an immediate activist campaign.

The reporting entities form a layered ownership and control structure culminating with Adrianus van Herk holding depositary receipts and key management roles. The Schedule 13D language is broad, preserving options to communicate with the board or propose changes, which is standard for investors taking a material stake. The disclosure of source of funds and absence of legal proceedings reduces near-term governance risk; however, the size of the stake makes any future engagement credible to other shareholders and the board.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Based on 105,344,052 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of June 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on August 7, 2025.


SCHEDULE 13D


Van Herk Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Van Herk Investments THI B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Van Herk Private Equity Investments B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Stichting Administratiekantoor Penulata
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Van Herk Management Services B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
A. van Herk Holding B.V.
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Stichting Administratiekantoor Abchrys
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Adrianus van Herk
Signature:/s/ Erik G.A. Esveld
Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
Date:09/30/2025
Comments accompanying signature:
* Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

FAQ

What percentage of ProQR (PRQR) does Van Herk now own?

The Van Herk reporting group beneficially owns 14,329,690 ordinary shares, equal to 13.6% of ProQR based on 105,344,052 shares outstanding as of June 30, 2025.

How many shares did Van Herk recently acquire and for how much?

Van Herk Investments B.V. acquired 1,055,000 ordinary shares in open-market transactions from September 5 to September 29, 2025 for an aggregate net amount of $2,300,635.14.

What was the source of funds for the share purchases?

The filing states the purchases were funded from the general working capital of Van Herk Investments B.V.

Did the filing state any intent to change ProQR's board or operations?

The Reporting Persons said the shares were acquired for investment purposes but reserved the right to review their investment and potentially engage with management, propose changes to board composition or pursue strategic transactions.

Are there any legal proceedings disclosed against the Reporting Persons?

No. The filing states that during the last five years none of the Reporting Persons has been convicted in a criminal proceeding or been subject to specified civil enforcement orders.
Proqr Therapeuti

NASDAQ:PRQR

PRQR Rankings

PRQR Latest News

PRQR Latest SEC Filings

PRQR Stock Data

248.61M
86.34M
18.04%
51.67%
0.52%
Biotechnology
Healthcare
Link
Netherlands
Leiden